Renowned Gynaecologist Joins Manipal Hospital Gurugram to Strengthen Women's Health
GURUGRAM, India, June 12, 2025 /PRNewswire/ — Manipal Hospital, one of the leading healthcare institutions in Gurugram, welcomes renowned surgeon Dr Amita Shah, Chairman & HOD, Obstetrics & Gynecology, Laparoscopy Endoscopy. Dr Shah has joined the expert team of Manipal Hospital Gurugram, to strengthen and enhance the medical expertise of healthcare delivery to the people of Gurugram. Through dedicated women's wellness and preventive health initiatives, she contributes to early detection and long-term health planning.
Dr Amita Shah will further enhance Manipal Hospital's expertise with extensive knowledge and experience spanning more than 29 years in diagnosing and treating numerous complex gynaecological issues. She is an expert in procedures like 3D and Robotic-Assisted Laparoscopic Gynaecological Surgeries, Gynae Oncology – Screening & Management, Infertility & Reproductive Endocrinology and many more. Her focus is to provide preventive health, advanced management of gynaecological disorders, and fertility care through a dedicated specialty clinic that has cutting-edge technology to treat advanced gynaecological issues. She is an active member of the Indian Fertility Society (IFS) and the Indian Association of Gynae Endoscopists (IAGE). Her addition to the team strengthens the hospital's capabilities in providing comprehensive heart care.
Dr Shah practices a 360-degree approach to women's health, providing care from conception through childbirth and postnatal vaccination, making Manipal Hospital a one-stop destination for maternity and reproductive care. She will play a key role in various Obstetrics and Gynecological programs such as Spandan, a parent support initiative aimed at easing the journey of parenthood through expert-led educational sessions and Manipal Sakhi, a comprehensive health card packed with exclusive patient benefits for women.
Expressing his enthusiasm for joining the team, Navin Pascal, Hospital Director, Manipal Hospital, Gurugram, said, 'We are delighted to have Dr Amita Shah in our team of medical experts. With a wealth of experience in women's healthcare, Dr. Shah brings with her a deep commitment to clinical excellence and patient-centered care. Her expertise across complex gynaecological procedures, high-risk obstetrics, and holistic reproductive health makes her a valuable addition to our multidisciplinary team. With her being a part of Manipal Hospital, we will be able to deliver advanced clinical management of gynaecological disorders, including minimally invasive and robotic surgeries for faster recovery and improved outcomes. At Manipal Hospital, we are dedicated to continuously enhancing the quality and scope of our healthcare services. Her joining marks a significant step in our ongoing efforts to elevate healthcare standards in Gurugram and assure our position as a trusted leader in women's health.'
About Manipal Hospitals
As a pioneer in healthcare, Manipal Hospitals is among the top healthcare providers in India serving over 7 million patients annually. Its focus is to develop an affordable, high quality healthcare framework through its multispecialty and tertiary care delivery spectrum and further extend it to out of hospital care. With the completion of acquisition of Medica Synergie hospitals and AMRI Hospitals Limited (acquired in Sept 2023), the integrated network today has a pan-India footprint of 37 hospitals across 19 cities with 10,500+ beds, and a talented pool of 5,600+ doctors and an employee strength of over 18,600.
Manipal Hospitals provides comprehensive curative and preventive care for a multitude of patients from around the globe. Manipal Hospitals is NABH, AAHRPP accredited and most of the hospitals in its network are NABL, ER, Blood Bank accredited and recognized for Nursing Excellence. Manipal Hospitals has also been recognised the most respected and patient recommended hospital in India through various consumer surveys
Photo – https://mma.prnewswire.com/media/2709681/Munipal_Hospitals_Dr_Amita_Shah.jpgPhoto – https://mma.prnewswire.com/media/2709682/Munipal_Hospitals_Photo.jpgLogo – https://mma.prnewswire.com/media/1941277/5194308/Manipal_Hospital_Logo.jpg
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
7 hours ago
- Malaysian Reserve
Weekly Recap: 11 Health Press Releases You Need to See
A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including advances in sleep apnea treatments, fall detection for seniors and diabetes research. NEW YORK, June 13, 2025 /PRNewswire/ — With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Klotho Neuroscience, Inc. Announces an Approach to Increase Longevity and Healthy Life Span – Replace a Silenced Gene Called Alpha-Klotho ('α-Klotho')Recent clinical and pre-clinical studies and analysis indicates the potential to increase lifespan and reduce age-associated degeneration in multiple organ systems has be realized with a focus on the human gene called Klotho. Mosanna Therapeutics Launches with $80 Million to Advance Novel Nighttime Nasal Spray for Obstructive Sleep ApneaDespite OSA's prevalence, treatment has largely focused on mechanical solutions that are often uncomfortable and disruptive. Mosanna is pioneering a pharmaceutical solution for sleep apnea patients with MOS118, a nasal spray administered at bedtime that helps restore the body's natural airway reflex. Sage Adds AI-Powered Fall Detection and Wellness Trend Monitoring to its All-in-One Senior Care PlatformDespite the best efforts of frontline care teams, falls remain the leading cause of injury and liability in senior living. That's why the team developed Sage Detect, which uses advanced AI to interpret daily activity patterns with highly granular data points to deliver real-time emergency alerts and wellness trend insights. Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value RightThe Elevation Oncology Board of Directors has unanimously determined that the acquisition by Concentra is in the best interests of all Elevation Oncology stockholders and has approved the Merger Agreement and related transactions. Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated CardiomyopathyLMNA-related dilated cardiomyopathy (LMNA DCM) is one of the most aggressive forms of DCM, affecting approximately 100,000 individuals in the United States and Europe, who progress rapidly to end-stage heart failure. NVC-001 demonstrated significant benefits, including survival and cardiac function in preclinical models. Enters into Collaboration with Mayo Clinic for AI Co-Innovation ProjectCurrently deployed across 70+ health systems, unified platform enables hospitals to deliver AI-assisted services such as ambient documentation, digital whiteboards, patient engagement, and hospital-at-home services, all through a deeply integrated, enterprise-grade solution. The American Diabetes Association Debuts the 85th Scientific Sessions with Breakthrough Diabetes Research'This year's agenda showcases our dedication to pushing the boundaries of research, encouraging innovation, and ultimately enhancing the lives of people living with diabetes and obesity,' said Rita Rastogi Kalyani, MD, MHS, the ADA's president of medicine and science. Deep Apple Therapeutics Announces Collaboration with Novo Nordisk to Discover and Develop Oral Therapeutics for Cardiometabolic DiseasesDeep Apple will discover and optimize compounds using its proprietary drug discovery platform, which combines machine-learning-powered virtual screening with structural biology enabled by cryo-electron microscopy (cryo-EM). Novo Nordisk will receive exclusive global rights to develop, manufacture, and commercialize the resulting compounds and products in all indications. U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus'If treated early with safe and effective therapies, providers can cure virtually all patients with hepatitis C before it escalates to chronic disease and eventually cirrhosis or liver cancer,' said John Ward, M.D., director, Coalition for Global Hepatitis Elimination. With this approval, providers can now treat HCV patients immediately at the time of diagnosis. A Safe Raw Milk Breakthrough: Tamarack Biotics Earns FDA Acceptance of Innovative TreatmentUsing advanced UV light technology, Tamarack's TruActive® process eliminates harmful pathogens while preserving the enzymes, proteins and immunity-supporting compounds that are often destroyed by traditional heat-based pasteurization. Cigna Healthcare Unveils Industry-Leading AI-Powered Digital Tools for a Simple and Reliable Customer ExperienceThe new digital features, which were developed with rigorous research and testing within a comprehensive artificial intelligence (AI) governance framework, are being made available in a phased rollout through Cigna Healthcare's myCigna member portal. They include an AI-powered virtual assistant, personalized provider matching, smart claim submission and more. For more news like this, check out all of the latest health-related releases from PR Newswire. Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most. Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers, and freelancers have access to the following free features: Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story. Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles. Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more. About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at
Malaysian Reserve
9 hours ago
- Malaysian Reserve
Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Greece
MELBOURNE, Australia, June 13, 2025 /PRNewswire/ –Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix', 'the Company') today announces that its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by the Greek EOF[2] for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer – a broad clinical label. This approval enhances the options available to healthcare providers across Greece for PSMA-PET[3] imaging using a clinically-validated, gallium-based radiopharmaceutical. Illuccix, after radiolabelling with gallium-68, is indicated in Greece for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings: Primary staging of patients with high-risk PCa prior to primary curative therapy. Suspected recurrent PCa in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy. Identification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer (mCRPC) for whom PSMA-targeted therapy is indicated. PSMA-PET imaging represents a significant advancement in prostate cancer management, providing clinicians with more information than conventional imaging methods (bone scan, CT[4] scan) thereby offering a new standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease and evaluation of BCR[5]. Illuccix PSMA-PET will help fulfil a critical unmet need by facilitating access to timely and effective diagnosis and patient selection for treatment with PSMA-targeted therapy. Access to PSMA-PET imaging in Greece remains extremely limited. During 2024, tracer and staff shortages meant that only 1,600 PSMA-PET examinations were conducted nationally, representing a small fraction of the 7,000 patients newly diagnosed each year. Illuccix's broad approval, supported by robust clinical data including the largest Ga-68-based PSMA data set from the VISION trial[6], will help address these challenges. Dr. Theodore Pipikos, Head of Nuclear Medicine and PET/CT at Hygeia Hospital, Athens, welcomed the decision, commenting, 'The approval of Illuccix marks a significant step forward in prostate cancer imaging for men in Greece. Given the structural barriers in our healthcare system, Illuccix provides healthcare practitioners with a widely accessible and much-needed tool to improve diagnostic accuracy.' Raphaël Ortiz, Chief Executive Officer, Telix International, added, 'The approval of Illuccix in Greece will support more widely available PSMA-PET imaging, and enable more healthcare providers and their patients to benefit from the convenience and flexibility of generator-produced gallium. This milestone reinforces Telix's ongoing commitment to advancing prostate cancer care and expanding access to innovative diagnostic and therapeutic radiopharmaceuticals across Europe'. Illuccix will be made available in Greece through Telix's distribution partner BIOKOSMOS S.A. a key radiopharmaceutical manufacturer in Greece with a comprehensive distribution network, which covers the full Greek Territory as well as Cyprus. Healthcare professionals in Greece interested in ordering Illuccix or learning more about availability can contact orders@ or call +30 22920 63900. Prostate Cancer in Greece Prostate cancer is the most common cancer for men in Greece with over 7,000 new cases diagnosed annually, and a significantly higher incidence in men than either bowel cancer (4,346 new cases) or lung cancer (6,357 new cases). Prostate cancer is the third most common cause of cancer death in men in Greece, with just over 1,900 men dying from their disease in 2022[7]. About Illuccix Telix's prostate imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the United States Food and Drug Administration (FDA)[8], by the Australian Therapeutic Goods Administration (TGA)[9], by Health Canada[10], by the Brazilian Health Regulatory Agency (ANVISA)[11], by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA)[12], by the French National Agency for the Safety of Medicine and Health Products (ANSM)[13], by the German Federal Institute for Drugs and Medical Devices (BfArM), and in multiple countries within the European Economic Area (EEA)[14] following a positive decentralized procedure (DCP) opinion by the German medical regulator[15]. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. [1] Positron emission tomography. [2] ΕΟΦ, Εθνικός Οργανισμός Φαρμάκων (National Organization for Medicines). [3] Imaging of prostate-specific membrane antigen with positron emission tomography. [4] Computed tomography. [5] EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3.: Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2023: [6] ID: NCT03511664. VISION study sponsored by Endocyte, a Novartis company. Telix provided Illuccix (TLX591-CDx) for PSMA-PET imaging. [7] Global Cancer Statistics 2022: GLOBOCAN survey. Published August 2024. [8] Telix ASX disclosure 20 December 2021. [9] Telix ASX disclosure 2 November 2021. [10] Telix ASX disclosure 14 October 2022. [11] Telix ASX disclosure 18 March 2025. [12] Telix ASX disclosure 13 February 2025. [13] Telix media release 29 April 2025. [14] Czech Republic, Denmark, Finland, Greece, Ireland, Luxembourg, Malta, the Netherlands, Norway, Portugal and Sweden at time of release. [15] Telix ASX disclosure 17 January 2025. Logo – View original content:
Malaysian Reserve
a day ago
- Malaysian Reserve
Renowned Gynaecologist Joins Manipal Hospital Gurugram to Strengthen Women's Health
GURUGRAM, India, June 12, 2025 /PRNewswire/ — Manipal Hospital, one of the leading healthcare institutions in Gurugram, welcomes renowned surgeon Dr Amita Shah, Chairman & HOD, Obstetrics & Gynecology, Laparoscopy Endoscopy. Dr Shah has joined the expert team of Manipal Hospital Gurugram, to strengthen and enhance the medical expertise of healthcare delivery to the people of Gurugram. Through dedicated women's wellness and preventive health initiatives, she contributes to early detection and long-term health planning. Dr Amita Shah will further enhance Manipal Hospital's expertise with extensive knowledge and experience spanning more than 29 years in diagnosing and treating numerous complex gynaecological issues. She is an expert in procedures like 3D and Robotic-Assisted Laparoscopic Gynaecological Surgeries, Gynae Oncology – Screening & Management, Infertility & Reproductive Endocrinology and many more. Her focus is to provide preventive health, advanced management of gynaecological disorders, and fertility care through a dedicated specialty clinic that has cutting-edge technology to treat advanced gynaecological issues. She is an active member of the Indian Fertility Society (IFS) and the Indian Association of Gynae Endoscopists (IAGE). Her addition to the team strengthens the hospital's capabilities in providing comprehensive heart care. Dr Shah practices a 360-degree approach to women's health, providing care from conception through childbirth and postnatal vaccination, making Manipal Hospital a one-stop destination for maternity and reproductive care. She will play a key role in various Obstetrics and Gynecological programs such as Spandan, a parent support initiative aimed at easing the journey of parenthood through expert-led educational sessions and Manipal Sakhi, a comprehensive health card packed with exclusive patient benefits for women. Expressing his enthusiasm for joining the team, Navin Pascal, Hospital Director, Manipal Hospital, Gurugram, said, 'We are delighted to have Dr Amita Shah in our team of medical experts. With a wealth of experience in women's healthcare, Dr. Shah brings with her a deep commitment to clinical excellence and patient-centered care. Her expertise across complex gynaecological procedures, high-risk obstetrics, and holistic reproductive health makes her a valuable addition to our multidisciplinary team. With her being a part of Manipal Hospital, we will be able to deliver advanced clinical management of gynaecological disorders, including minimally invasive and robotic surgeries for faster recovery and improved outcomes. At Manipal Hospital, we are dedicated to continuously enhancing the quality and scope of our healthcare services. Her joining marks a significant step in our ongoing efforts to elevate healthcare standards in Gurugram and assure our position as a trusted leader in women's health.' About Manipal Hospitals As a pioneer in healthcare, Manipal Hospitals is among the top healthcare providers in India serving over 7 million patients annually. Its focus is to develop an affordable, high quality healthcare framework through its multispecialty and tertiary care delivery spectrum and further extend it to out of hospital care. With the completion of acquisition of Medica Synergie hospitals and AMRI Hospitals Limited (acquired in Sept 2023), the integrated network today has a pan-India footprint of 37 hospitals across 19 cities with 10,500+ beds, and a talented pool of 5,600+ doctors and an employee strength of over 18,600. Manipal Hospitals provides comprehensive curative and preventive care for a multitude of patients from around the globe. Manipal Hospitals is NABH, AAHRPP accredited and most of the hospitals in its network are NABL, ER, Blood Bank accredited and recognized for Nursing Excellence. Manipal Hospitals has also been recognised the most respected and patient recommended hospital in India through various consumer surveys Photo – – –
